The impact of antiviral therapy on the course of chronic HCV infection: A systematic review

Panminerva Medica

Volumn 45, Issue 3, 2003, Pages 175-182

  Almasio, P L ^a,b   Venezia, G ^a   Craxi A ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Laboratory of Virology   (Italy)

Author keywords

Antiviral agents; Hepatitis C; Interferons; Liver cirrhosis

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; CALCULATION; COMPARATIVE STUDY; DATA BASE; DISEASE COURSE; DRUG RESPONSE; FOLLOW UP; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INCIDENCE; LITERATURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MEDLINE; PUBLICATION; RELAPSE; REMISSION; REVIEW; RISK REDUCTION; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; PROGNOSIS; RISK FACTORS; VIRUS REPLICATION;

EID: 0346731027     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. EASL International Consensus Conference on Hepatitis C, Paris, 26-28 February 1999. Consensus Statement. J Hepatol 1999;30:956-61.
2. Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997;26 Suppl 1:15-20.
3. Marcellin P. Hepatitis C: clinical spectrum of the disease. J Hepatol 1999;31 Suppl 1:9-16.
4. De Bac C, Stroffolini T, Gaeta GB, Taliani G, Giusti G. Pathogenic factors in cirrhosis with and without hepatocellular carcinoma: a multicenter Italian study. Hepatology 1994;20:1225-30.
5. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32 Suppl 1:98-112.
6. Powell DW, Abramson BZ, Balint JA, Belle S, Bloomer JR, Diehl AK et al. National Institutes of Health Consensus Development Conference panel statement: management of hepatitis C. Hepatology 1997;26 Suppl 3:2-10.
7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
8. Fried MW, Shiffman ML, Reddy RK, Smith C, Marinos G, Goncales FL jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette jr H et al. Pegintron α-2a (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and dose. J Hepatol 2001;346 Suppl 1:3.
10. Poynard T, McHutchison J, Davis G, Esteban R, Albrecht J, Ling M et al. Durability of viral response to interferon ribarivin combination in patients with chronic hepatitis C. J Hepatol 2001;34 Suppl 1:23.
11. Craxì A, Cammà C, Giunta C. Definition of response to antiviral therapy in chronic hepatitis C. J Hepatol 1999;31 Suppl 1:160-7.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
13. Shindo M, Di Biscaglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992;15:1013-6.
14. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993;18: 1300-5.
15. Marcellin P, Boyer N, Degott C, Martinot-Peignoux M, Duchatelle V, Giostra E et al. Long term histological and viral changes in patients with chronic hepatitis C who responded to α-interferon. Liver 1994;14:302-7.
16. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sonnerborg A et al. Two-year biochemical, virological and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon α-2b treatment. Hepatology 1995; 21:918-22.
17. Teuber G, Dienes HP, Meyer zum Buschenfelde KH, Gerken G. Long term follow-up of patients with chronic hepatitis C after interferon-α treatment. Digestion 1996;57:464-71.
18. Hagiwara H, Hayashi N, Kasahara A, Oshita M, Katayama K, Naito M et al. Long-term biochemical and virological response to natural interferon-α in patients with chronic hepatitis C. Dig Dis Sci 1996;41:1001-7.
19. Vento S, Concia E, Ferraro T. Lack of sustained efficacy of interferon in patients with chronic hepatitis C. N Engl J Med 1996;334: 1479-80.
20. Marcellin P, Boyer N, Gervais A, Martinot-Peignoux M, Pouteau M, Castelnau C et al. Long term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to α-interferon therapy. Ann Intern Med 1997;127:875-81.
21. Manesis EK, Papaioannou C, Gioustozi A, Kafiri G, Koshinas J, Hadziyannis SJ. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon α-2b for 6 or 12 months: a 4-year follow-up of 211 patients. Hepatology 1997;26: 734-39.
22. Berg T, Kaul T, Heuft HG, Naumann U, Lobeck H, Wiedenmann B et al. Long-term efficacy of interferon a treatment in chronic hepatitis C. J Hepatol 1998;29:511-2.
23. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10-Year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology 1998;28:1121-7.
24. Cammà C, Di Marco V, Lo Iacono O, Almasio P, Giunta M, Fuschi P et al. Long-term course of interferon-treated chronic hepatitis C. J Hepatol 1998;28:531-7.
25. Sim H, Yim C, Krajden M, Heathcote J. Durability of serological remission in chronic hepatitis C treated with interferon-α-2b. Am J Gastroenterol 1998;93:39-43.
26. Morisco F, Tuccillo C, Iasevoli P, Sessa G, Brunasso G, Caporaso N. Chronic hepatitis C long-term responders to human leukocyte interferon-α therapy: persistence of a sustained biochemical and virological response during 5 years of surveillance. Eur J Gastroenterol Hepatol 1998;10:399-403.
27. Reichard O, Glaumann H, Frygén A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to α interferon. J Hepatol 1999;30:783-7.
28. Morisco F, Marmo R, Iasevoli P, Sessa G, Tuccillo C, Del Vecchio Blanco C et al. Clinical outcome of chronic hepatitis C in patients treated with interferon: a comparison between responders and non responders. It J Gastroenterol Hepatol 1999;31:454-8.
29. Garcia-Bengoechea M, Basaras M, Barrio J, Arrese E, Montalvo II, Arenas JI et al. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after α-interferon therapy. Am J Gastroent 1999;94:1902-5.
30. Barnes E, Webster G, Jacobs R, Dusheiko G. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin. J Hepatol 1999;31 Suppl 1:244-9.
31. Schvarcz R, Glaumann H, Reichard O, Weiland O. Histological and virological long-term outcome in patients treated with interferon-α2b and ribavirin for chronic hepatitis C. J Viral Hepatitis 1999;6: 237-42.
32. Collier JD, Adams PA, Feinman V, Ghent C, Witt-Sullivan H, Minuk G et al. Long term follow-up of patients with chronic hepatitis C treated with interferon α. Can J Gastroenterol 2000;14 Suppl B:77-80.
33. Shindo M, Hamada K, Oda K, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology 2001;33:1299-302.
34. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A et al. Long-term beneficial effects in sustained responders to interferon-α therapy for chronic hepatitis C. J Hepatol 2001;34:748-55.
35. Cammà C, Giunta M, Linea C, Pagliaro L. The effect of interferon on liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
36. Giannini E, Fasoli A, Botta F, Testa E, Romagnoli P, Ceppa P et al. Long-term follow up of chronic hepatitis C patients after alpha-interferon treatment: a functional study. J Gastroenterol Hepatol 2001;16:399-405.
37. Ajello A, Freni MA, Spadaro A, Alessi N, Impellizzeri F, Consolo P et al. Ten years follow-up of patients with chronic hepatitis C treated with interferon. Hepatogastroenterology 1999;46:2447-50.
38. Ikeda K, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol 2001;16: 406-15.
39. Imai Y, Kawata S, Tamura S, Yabuchi I, Noda S, Inada M et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-9.
40. Toyoda H, Kumada T, Tokuda A, Horiguchi Y, Nakano H, Honda T et al. Yon-Ken HCV-HCC Follow-up Study Group. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat 2000;7:414-9.
41. Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep 1998;5:205-8.
42. Miyajima I, Sata M, Kumashiro R, Uchimura Y, Ide T, Suzuki H et al. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncol Rep 1998;5:201-4.
43. Bernardiniello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnù L et al. Long-term clinical outcome after β-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999;46:3216-22.
44. Gramenzi A, Andreone P, Fiorino S, Cammà C, Giunta M, Magalotti D et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-8.
45. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
46. Sata M, Ide T, Akiyoshi F, Fukuizumi K, Noguchi S, Shirachi M et al. Effects of interferon α 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group. Kurume Med J 1997;44:171-7.
47. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F et al. Effectiveness of interferon α on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997;27: 201-5.
48. Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999;131:174-81.
49. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-9.
50. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
51. Tong MJ, El-Farra NS, Reijes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-6.
52. Niederau C, Lange S, Heintges T, Erhardt A, Bushkamp M, Hurter D et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998;28:1687-95.
53. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112: 463-72.
54. Serfaty L, Aumaitre H, Chazouillères O, Bonnand AM, Rosdmorduc O, Poupon RE et al. Determinants of outcomes of compensated hepatitis C virus related cirrhosis. Hepatology 1998;27:1435-40.
55. Pagliaro L, Peri V, Linea C, Cammà C, Giunta M, Magrin S. Natural history of chronic hepatitis C. It J Gastroenterol Hepatol 1999;31: 28-44.
56. Poynard T, Bedossa P, Opolon P for the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825-32.
57. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
58. Wiley TE, Mc Carthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998;28:805-9.
59. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M et al. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case-control study in Italy. Hepatology 1997;26: 579-84.
60. Soriano V, Garcia-Samaniego J, Rodriguez-Rosado R, Gonzàlez J, Pedreira J. Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. J Hepatol 1999;31 Suppl 1:119-23.
61. Pontisso P, Gerotto M, Benvegnù L, Chemello L, Alberti A. Co-infection with hepatitis B and C viruses. In: Schinanzi RF, Sommadossi J-P, Thomas HC, editors. Therapies for viral hepatitis. London, UK: International Medical Press; 1998. p.417-22.
62. Davis GL, Balart LA, Schiff ER, Linsday K, Bodenheimer HC jr, Perillo RP et al. Treatment of chronic hepatitis C with recombinant interferon α. A multicenter randomized, controlled study. N Engl J Med 1989;321:1501-6.
63. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J et al. Recombinant interferon α therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
64. Tinè F, Magrin S, Craxì A, Pagliaro L. Interferon for non-A non-B chronic hepatitis: a meta-analysis of randomised clinical trials. J Hepatol 1991;13:192-9.
65. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996;24:778-89.
66. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
67. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al. A comparison of three interferon α-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
68. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon α-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-96.
69. Carithers RL, Emerson S. Therapy of hepatitis C: meta-analysis of interferon α-2b trials. Hepatology 1997;26 Suppl 1:83-8.
70. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998;352: 1426-32.
71. Chemello L, Cavaletto L, Bernardiniello E, Guido M, Pontisso P, Alberti A. The effect of interferon α and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995;23: 8-12.
72. Reichard O, Norkrans G, Frydén A, Braconier JH, Sonneborg A, Weiland O for the Swedish Study Group. Randomised, double-blind, placebo-controlled trial of interferon α2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83-7.
73. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HT. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991;14:969-74.
74. Tremolada F, Casarin C, Alberti A, Drago C, Tagger A, Ribero MI et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol 1992;16: 273-81.
75. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL et al. Long term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992;327:1906-11.
76. Kowdley K. Interferon alfa for chronic hepatitis C: how do we define cure? Gastroenterology 1998;115:501-3.